The benefits of immunotherapy and the impact of available therapies for metastatic melanoma on the clinical outcome of patients in the Unified Health System (SUS)
DOI:
https://doi.org/10.33448/rsd-v14i5.48809Keywords:
Melanoma; Immunotherapy; Unified Health System; Public Health; Antineoplastic Agents.Abstract
Melanoma is a type of skin cancer that originates in melanocytes and can manifest itself in any region of the body in the form of spots, nevi or moles. It accounts for 3% of cutaneous neoplasms and has a high metastatic capacity and mortality rate. The aim of this study was to assess the benefits of immunotherapy on progression-free survival and overall survival in relation to the standard therapy available for the treatment of metastatic melanoma in the Unified Health System (SUS). A narrative review was carried out, analyzing 18 scientific articles selected from the PubMed, Cochrane and Scielo databases, covering the last 10 years. The inclusion criteria were complete articles in Portuguese, English or Spanish, including systematic reviews, meta-analyses and cohort or randomized studies. The data obtained reinforces the greater efficacy and lower toxicity of immunotherapy compared to chemotherapy with dacarbazine in the treatment of metastatic melanoma, highlighting it as a promising therapeutic alternative. Despite the superior clinical outcome of immunotherapy over chemotherapy with dacarbazine, especially with regard to progression-free survival and overall survival, challenges remain regarding its widespread implementation in the SUS, especially in the financial sphere. This highlights the need to develop strategies aimed at democratizing access to immunotherapy in the context of metastatic melanoma, since, despite the high cost, the benefit for patients with advanced metastatic melanoma is undeniable, with a significant improvement in quality of life.
References
Agência Nacional de Vigilância Sanitária (ANVISA). (2015). Medicamentos guia nº 03/2015 - versão 1 guia para desfechos para estudos clínicos de medicamentos oncológicos. https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/medicamentos/publicacoes-sobre-medicamentos/desfechos-para-estudos-clinicos-de-medicamentos-oncologicos.pdf
Boutros, A., Enrica Teresa Tanda, Croce, E., Catalano, F., Marcello Ceppi, Bruzzone, M., Cecchi, F., Luca Arecco, Matteo Fraguglia, Paolo Pronzato, Genova, C., Lucia Del Mastro, Matteo Lambertini, & Spagnolo, F. (2023). Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. European Journal of Cancer, 188, 64–79. https://doi.org/10.1016/j.ejca.2023.04.010
Brasil. (2013). Portaria nº 874, de 16 de maio de 2013: Institui a Política Nacional para a Prevenção e Controle do Câncer na Rede de Atenção à Saúde das Pessoas com Doenças Crônicas no âmbito do Sistema Único de Saúde (SUS). Diário Oficial da União, 94(Seção 1), 129–132. https://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt0874_16_05_2013.html
Brasil. (2022a). Portaria Conjunta nº 19, de 25 de outubro de 2022: Aprova as Diretrizes Diagnósticas e Terapêuticas do Melanoma Cutâneo. Diário Oficial da União, 210 (Seção 1), 69.
https://www.gov.br/conitec/pt-br/midias/protocolos/ddt/20221109_ddt_melanoma_cutaneo.pdf
Brasil. (2022b). Portaria GM/MS nº 638, de 28 de março de 2022: Altera atributos de procedimentos e exclui procedimentos da Tabela de Procedimentos, Medicamentos, Órteses, Próteses e Materiais Especiais do Sistema Único de Saúde - SUS. Diário Oficial da União, 60(Seção 1), 121–123.
https://bvsms.saude.gov.br/bvs/saudelegis/gm/2022/prt0638_29_03_2022.html
Brasil. (2022c). Secretaria de atenção especializada à saúde departamento de regulação, avaliação e controle coordenação-geral de gestão dos sistemas de informações em saúde SIA/SUS sistema de informações ambulatoriais oncologia manual de bases técnicas agosto/2022 Brasília-DF - Brasil 30ª edição. https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//manual_oncologia_30a_edicao_agosto_2022_25_08_2022_-_26-08-2022.pdf
Casarin, S. T. et al. (2020). Tipos de revisão de literatura: considerações das editoras do Journal of Nursing and Health. Journal of Nursing and Health. 10 (5). https://periodicos.ufpel.edu.br/index.php/enfermagem/article/view/19924.
Cazzato, G., Colagrande, A., Cimmino, A., Abbatepaolo, C., Bellitti, E., Romita, P., Lospalluti, L., Foti, C., Arezzo, F., Loizzi, V., Lettini, T., Sablone, S., Resta, L., Cormio, G., Ingravallo, G., & Rossi, R. (2021). GLUT1, GLUT3 Expression and 18FDG-PET/CT in Human Malignant Melanoma: What Relationship Exists? New Insights and Perspectives. Cells, 10(11), 3090. https://doi.org/10.3390/cells10113090
CiRen, B., Wang, X., & Long, Z. (2016). The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget, 7(49), 81493–81511. https://doi.org/10.18632/oncotarget.13277
Coen, O., Corrie, P., Marshall, H., Plummer, R., Ottensmeier, C., Hook, J., Bell, S., Sagoo, G. S., Meads, D., Bestall, J., Velikova, G., Gallagher, F. A., Smith, A., Howard, H., Mason, E., Katona, E., Silva, S., Collinson, M., Rodwell, S., & Danson, S. (2021). The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21(1), 761. https://doi.org/10.1186/s12885-021-08509-w
Comissão Nacional de Incorporação de Tecnologias no SUS (CONITEC). (2020). Terapia-alvo (vemurafenibe, dabrafenibe, cobimetinibe, trametinibe) e imunoterapia (ipilimumabe, nivolumabe, pembrolizumabe) para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático. https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2019/sociedade/resoc189_terapiaalvo_imunoterapia_melanoma.pdf
Dinnes, J., Deeks, J. J., Chuchu, N., Ferrante di Ruffano, L., Matin, R. N., Thomson, D. R., Wong, K. Y., Aldridge, R. B., Abbott, R., Fawzy, M., Bayliss, S. E., Grainge, M. J., Takwoingi, Y., Davenport, C., Godfrey, K., Walter, F. M., & Williams, H. C. (2018). Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd011902.pub2
Diogo, R., Leopoldo, & Garicochea, B. (2017). Cancer immunology and melanoma immunotherapy. Anais Brasileiros de Dermatologia, 92(6), 830–835. https://doi.org/10.1590/abd1806-4841.201756511
Garrett, S., Cristina, A., Elaine Barros Ferreira, Damiani, G., Elaine, P., & Christiane Inocêncio Vasques. (2021). Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLOS ONE, 16(8), e0255716–e0255716. https://doi.org/10.1371/journal.pone.0255716
Gil, A. C. (2017). Como elaborar projetos de pesquisa. 6ªed. Atlas.
Guerra, R. L., Corrêa, F. de M., Fernandes, R. R. A., & Zimmerman, I. R. (2019). Cost Utility of Target Therapies Compared to Dacarbazine for First-Line Treatment of Advanced Non-Surgical and Metastatic Melanoma in the Brazilian National Health System. Value in Health Regional Issues, 20, 103–109. https://doi.org/10.1016/j.vhri.2019.04.001
Grupo Brasileiro Melanoma. (2021). Melanoma. https://gbm.org.br/wp-content/uploads/2021/09/cartilhamelanoma_GBM.pdf
Instituto Nacional de Câncer (INCA). (2022). Câncer de pele melanoma. https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/pele-melanoma
Instituto Nacional de Câncer (INCA). (2021). Detecção precoce do câncer. https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/deteccao-precoce-do-cancer.pdf
Kadhum, M., Shuber, E., Abdulhussein, D., & Sinclair, P. (2019). Who should carry out skin cancer excisions? A systematic review. Journal of Cutaneous and Aesthetic Surgery, 12(3), 153. https://doi.org/10.4103/jcas.jcas_174_18
Liu, S., Zhu, Y., Cheng, H., Zhong, M., Hu, Y., Li, Q., & Gao, X. (2021). The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis. Journal of Cancer Research and Therapeutics, 17(7), 1679. https://doi.org/10.4103/jcrt.jcrt_1669_21
Mangin, M., Boespflug, A., Boulch, D. M., Charles‐Hervé Vacheron, Carpentier, I., Thomas, L., & Dalle, S. (2021). Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. Cancer Medicine, 10(10), 3155–3164. https://doi.org/10.1002/cam4.3760
Mattos, P. C. (2015). Tipos de revisão de literatura. Unesp, 1-9. https://www.fca.unesp.br/Home/Biblioteca/tipos-de-evisao-de-literatura.pdf.
Pasquali, S., Hadjinicolaou, A. V., Chiarion Sileni, V., Rossi, C. R., & Mocellin, S. (2018). Systemic treatments for metastatic cutaneous melanoma. The Cochrane Database of Systematic Reviews, 2018(2). https://doi.org/10.1002/14651858.CD011123.pub2
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. Santa Maria/RS. Ed. UAB/NTE/UFSM.
Petrelli, F., Coinu, A., Cabiddu, M., Borgonovo, K., Ghilardi, M., Lonati, V., & Barni, S. (2016). Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. Medicine, 95(26), e3997–e3997. https://doi.org/10.1097/md.0000000000003997
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambiase, A., de Vincentiis, M., & Greco, A. (2020). Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. Journal of Immunology Research, 1–12. https://doi.org/10.1155/2020/9235638
Rangel-Sosa, M. M., Aguilar-Córdova, E., & Rojas-Martínez, A. (2017). Immunotherapy and gene therapy as novel treatments for cancer. Colombia Médica, v48(i3), 138–147. https://doi.org/10.25100/cm.v48i3.2997
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Rutkowski, P., Hassel, J. C., McNeil, C. M., Kalinka, E. A., Lebbé, C., Charles, J., Hernberg, M. M., Savage, K. J., Chiarion-Sileni, V., Mihalcioiu, C., Mauch, C., Arance, A., Cognetti, F., & Ny, L. (2020). Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. Journal of Clinical Oncology, 38(33), 3937–3946. https://doi.org/10.1200/jco.20.00995
Rodríguez, R., Parra, A., González, S., Molgó, M., Droppelmann, N., Acevedo, F., Peña, J., & Uribe, P. (2016). Entendiendo las terapias actuales en melanoma metastásico. Revista Médica de Chile, 144(11), 1448–1458. https://doi.org/10.4067/s0034-98872016001100011
Rother, E. T. (2007). Revisão sistemática x revisão narrativa. Acta Paul. Enferm. 20(2). https://doi.org/10.1590/S0103-21002007000200001.
Secretaria de Saúde do Paraná. (n.d.). Medicamentos Oncológicos. https://www.saude.pr.gov.br/Pagina/Medicamentos-Oncologicos
Tzellos, T., Kyrgidis, A., Mocellin, S., Chan, A.-W., Pilati, P., & Apalla, Z. (2014). Interventions for melanoma in situ, including lentigo maligna. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd010308.pub2
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M. S., Bechter, O., Maio, M., Marquez-Rodas, I., & Guidoboni, M. (2017). Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 377(14), 1345–1356. https://doi.org/10.1056/nejmoa1709684
Wong, A. Y. S., T. Frøslev, Dearing, L., Forbes, H. J., Mulick, A., Mansfield, K. E., Silverwood, R. J., A. Kjærsgaard, H.T. Sørensen, L. Smeeth, Lewin, A., Schmidt, S. A. J., & Langan, S. M. (2020). The association between partner bereavement and melanoma: cohort studies in the U.K. and Denmark. British Journal of Dermatology, 183(4), 673–683. https://doi.org/10.1111/bjd.18889
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Juliane Kaori Saito; Larissa Dayelle Osternack; Rayssa Helena de Sena; Michelle Simão
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
